MOTS-c: doses reported in published research

Sources checked 2026-10-07 · 3 cited studies (0 human, 3 animal, 0 cell culture) · 1 registered trial

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene, described in 2015. Published dose data are from mouse studies; human trials of MOTS-c or its analog CB4211 are registered without published results.

No human data. No published human dose data. A phase 2 trial (NCT07505745) is recruiting and its record states no amount; a phase 1 trial of the analog CB4211 (NCT03998514) lists doses only as "Dose 1-6".

Animal studies (3)

Animal doses are listed exactly as the studies report them. They are not converted to human amounts here; doses do not translate between species by body weight.

Animal Male CD-1 mice on a normal diet

Dose as reported: 5 mg/kg/day
Route: Not stated in this passage
Frequency / duration: BID for 4 days

Source wording: outbred CD-1 male mice fed a normal diet were treated acutely with MOTS-c (5 mg/kg/day; BID, 4 days) or vehicle control

Lee C, Zeng J, Drew BG et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015. PubMed PMID 25738459 ↗ · full text PMC4350682 ↗

Animal CD-1 mice on a high-fat diet

Dose as reported: 0.5 mg/kg/day
Route: Intraperitoneal
Frequency / duration: Daily; 3 weeks for the respiratory-exchange measurements

Source wording: we next tested the effects of MOTS-c (0.5 mg/kg/day; IP) on outbred CD-1 mice fed a high-fat diet Mice fed a HFD and treated with MOTS-c (0.5 mg/kg/day) for 3 weeks

Animal Young CD-1 mice

Dose as reported: 5 mg/kg/day; in a high-fat-diet arm, 5 or 15 mg/kg/day
Route: Intraperitoneal
Frequency / duration: Daily for 2 weeks

Source wording: treating young mice (CD-1; outbred) daily with MOTS-c [5 mg/kg/day; intraperitoneal injections (IP)] for 2 weeks treated them with 2 doses of MOTS-c (5 and 15 mg/kg/day; IP;

Reynolds JC, Lai RW, Woodhead JST et al.. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021. PubMed PMID 33473109 ↗ · full text PMC7817689 ↗

Registered trials (1)

From ClinicalTrials.gov records. Registry entries describe planned designs; they are not published results.

Registered trial (no published results) Adults, phase 2, recruiting; no results

Dose as reported: "Fixed dose"; amount not stated in the registry record
Route: Subcutaneous
Frequency / duration: Once daily for 12 weeks

Source wording: Fixed dose once daily for 12 weeks Route Subcutaneous injection

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. ClinicalTrials.gov registry record. NCT07505745 ↗

Half-life

No half-life value was found in the sources reviewed for this page.

About this page

Every figure above is copied from the cited source; the source wording is shown with each entry. Where a source does not state something, the page says so.
Only abstracts, open-access full texts, registry records and FDA labels were used, so details found only in a paywalled full text may be missing.
This page does not convert doses between species or into other measures, and gives no preparation or handling information.